Glenmark Pharmaceuticals has launched an offer on the Singapore Stock Exchange to raise up to $200 million through issue of securities. The Mumbai-based company has decided on a regulatory floor price for conversion of the FCCBs at Rs 861.84. JP Morgan Securities is the sole global coordinator and book-runner for the said issue.
Last year, the company’s board and shareholders had approved a plan to raise funds up to $500 million through issuance of securities, including shares or equity-linked assets, convertible bonds, warrants, and depository receipts.
Glenmark Pharmaceuticals is a pharmaceutical company headquartered in Mumbai, India. It manufactures and markets generic formulation products and active pharmaceutical ingredients, both in the domestic and international markets.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1677.45 |
| Dr. Reddys Lab | 1234.80 |
| Cipla | 1241.25 |
| Zydus Lifesciences | 948.10 |
| Lupin | 2332.55 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: